No Data
Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill -- WSJ
Hims & Hers Health Is Maintained at Underperform by B of A Securities
Novo-Nordisk A/S's share price surged over 7% again, while Hims halted its $49 weight-loss drug following FDA pressure.
① After Hims & Hers Health canceled the launch of a $49 generic weight-loss drug, shares of Novo-Nordisk A/S surged more than 7% in pre-market trading on Monday; ② The FDA stated it would strengthen regulation over compounded GLP-1 drugs, which investors viewed as reducing competitive threats to branded originator drugs, benefiting large pharmaceutical companies such as Novo-Nordisk A/S.
Needham Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Express News | Hims & Hers Health Inc : Citigroup Cuts Target Price to $16.5 From $30
Hims & Hers Health Analyst Ratings